Search tips
Search criteria 


Logo of jshaGuide for AuthorsAbout this journalExplore this journalJournal of the Saudi Heart Association
J Saudi Heart Assoc. 2016 July; 28(3): 159–166.
Published online 2015 July 2. doi:  10.1016/j.jsha.2015.06.002
PMCID: PMC4917708

Assessment of left ventricular mass index could predict metabolic syndrome in obese children



Childhood obesity is a major risk factor for cardiovascular diseases in children and adults.


The purpose of this study was to evaluate the serum leptin level and the cardiac changes in normotensive obese children and to study the relationship between left ventricular mass index (LVMI) and serum leptin with the parameters of metabolic syndrome (MS) in obese children.


This study was conducted in al Jeddani Hospital and Ibn Sina College Hospital in Saudi Arabia in the period from July 2012 to December 2013, and included 82 obese children. Their mean age was 10.2 ± 2.8 years; they were divided into 25 obese children with MS and 57 obese children without MS, and 40 healthy age- and sex-matched children were also included in the study as a control group. All children were subjected to clinical assessment including standing height, body weight, body mass index (BMI), waist circumference (WC), and blood pressure measurements. All children received an echocardiographic examination (2-dimensional, M-mode, Doppler, and tissue Doppler echocardiograpy) and laboratory assessment of serum leptin level, fasting glucose, fasting insulin, the homeostatic model assessment for insulin resistance (HOMA) index, total cholesterol, triglycerides, and high- and low-density lipoprotein profile.


BMI, BMI standard deviation score, WC, fasting glucose, fasting insulin, HOMA index and the serum leptin level were significantly higher in obese children compared to control group (p < 0.05). The LVMI were increased in the obese compared to the control group (p < 0.001) while left ventricle systolic and diastolic functions did not differ in obese versus control group (> 0.05). There was a significant positive correlation between both LVMI and serum leptin level in comparison to BMI, WC, fasting glucose, fasting insulin, HOMA, triglycerides, and low-density lipoprotein in all obese children, especially the MS group. However, there was a significant negative correlation between both LVMI and serum leptin level in comparison to high-density lipoprotein.


Assessment of LVMI as routine echocardiographic examinations and serum leptin level might be a feasible and reliable method for the evaluation of obesity and its related cardiovascular risks during childhood that can predict metabolic syndrome and insulin resistance.

Keywords: Left ventricular mass index, Metabolic syndrome, Obese children, Serum leptin


left ventricular mass index
body mass index
waist circumference
homeostatic model assessment
tissue Doppler echocardiography
left ventricular mass
metabolic syndrome
homeostatic model assessment for insulin resistance
left ventricle
fasting glucose insulin ratio
high density lipoprotein
standard deviation score
early diastolic myocardial velocity


Obesity is currently regarded as a public health problem that affects both children and adults [1]. It has been shown that obesity is associated with the development of early myocardial and coronary artery changes in children and adolescent [2]. Therefore, prior to the onset of left ventricular systolic dysfunction, emergence of diastolic dysfunction in obese children might lead to diagnosis in a very early stage of the disease [3]. Obesity affects cardiovascular parameters such as left ventricular mass (LVM) and cardiac function as well as metabolic parameters such as insulin levels and glucose tolerance [4]. Tissue Doppler echocardiography (TDE) is a recent echocardiographic imaging technique that allows evaluation of regional myocardial systolic and diastolic function [5]. Metabolic syndrome (MS) is characterized by central obesity, insulin resistance, hyperglycemia, dyslipidemia, and hypertension [6]. Adipose tissue serves not only as an energy storage organ, but also as an endocrine organ by releasing factors into the circulation that have sites of action [7]. Leptin is a peptide hormone that is predominantly produced in adipose tissue [8]. In addition to its effect on neuroendocrine, immune, and reproductive systems, leptin regulates food intake, body weight, and energy homeostasis [9]. Increased adiposity was shown to be associated with hyperleptinemia, which subsequently causes endothelial dysfunction, hypertension, and cardiovascular diseases [10]. Leptin is proposed as biomarker in children for predicting MS, Type 2 diabetes, or cardiovascular disease [11]. This study aimed to assess the LVM index (LVMI) and serum leptin level in obese nonhypertensive children and their prediction to metabolic syndrome.

Patients and methods

A cross-sectional study that comprised 82 obese children and 40 healthy children was conducted in al Jeddani Hospital and Ibn Sina College Hospital in Saudi Arabia from July 2012 to December 2013. The obese group consisted of 82 children (47 boys and 35 girls) aged 6–14 years. Their mean ± standard deviation age was 10.2 ± 2.8 years and mean body mass index (BMI) 32.8 ± 4.6 kg/m2. The obese children had BMI [gt-or-equal, slanted]95th percentile for age and sex based on the standards of the Centers for Disease Control and Prevention.

The control group consisted of 40 children (22 boys and 18 girls) aged 6–14 years. Their mean age was 10.6 ± 2.7 years and their mean BMI was 18.7 ± 2.9 kg/m2. The control participants were recruited from a population of nonobese healthy children who presented to the hospital for minor illnesses. The obese patients were divided into the MS group (= 25) and non-MS group (= 57) according to the International Diabetes Federation consensus definition of MS in children and adolescents [12]. A local ethical committee was approved from our hospital (al Jeddani Hospital). Informed consent was obtained from parents of patients and controls. Children were excluded if they had: previous cardiac disease or taken medication known to affect cardiac function (antihypertensive drugs); an earlier major illness, including type 1 diabetes; taken medications; had a condition that is known to influence their growth, insulin action, or insulin secretion (e.g., glucocorticoid therapy, hypothyroidism, and Cushing’s disease); or liver disease or impaired liver functions (see Figure 1, Figure 2).

Figure 1
Doppler echocardiography showing reversed E/A ratio of the mitral valve flow.
Figure 2
Tissue Doppler echocardiography on the lateral mitral annulus showing normal early diastolic myocardial velocity.

Anthropometric measures

For each child, the height and weight were measured. The height was measured to the nearest 0.1 cm using a Holtain portable anthropometer (manufacturer, address), and the weight was determined to the nearest 0.01 kg using a Seca scale balance (manufacturer, address) with the patient dressed in minimal clothes and without shoes. The BMI was calculated as weight (in kg) divided by height (in m) squared. Waist circumference (WC) was measured at the level of the umbilicus with the child standing and breathing normally. Each measurement was taken as the mean of three consecutive measurements, using standardized equipment and following the recommendations of the International Biological Program.

Biochemical measurements

Fasting venous blood samples were collected in plain tubes using a standard venipuncture aseptic technique. The samples were allowed to clot and sera were separated by centrifugation and stored in aliquots at −80 °C until assayed. Fasting glucose was measured using a quantitative enzymatic colorimetric commercial kit provided by Stanbio according to the glucose oxidase method [14]. The human leptin assay utilized 125I-labeled human leptin and human leptin antiserum to determine leptin levels [15]. The detection limit of the assay was 0.5 ng/mL. Plasma concentrations of total cholesterol, high-density lipoprotein, low-density lipoprotein, and triglycerides were measured using routine enzymatic methods with Olympus 2700 Analyzer (Tokyo, Japan). Insulin levels were measured using a chemiluminescence immunoassay. The homeostatic model assessment for insulin resistance (HOMA-IR) index was calculated according to the following equation HOMA-IR = fasting insulin concentration (μU/mL) × fasting glucose concentration (mM)/22.5 [7].

Definitions of MS

Based on the MS criteria proposed by the International Diabetes Federation [12], patients were diagnosed as having MS when their WC was [gt-or-equal, slanted]90th percentile and when at least two of the following factors were present: (1) raised concentration of triglycerides: [gt-or-equal, slanted]150 mg/dL (1.7 mM) or receiving specific treatment for high triglycerides; (2) reduced concentration of high-density lipoprotein (HDL) cholesterol: <40 mg/dL (1.03 mM) or receiving specific treatment for this lipid abnormality; (3) raised blood pressure (BP): systolic BP [gt-or-equal, slanted]130 mmHg or diastolic BP [gt-or-equal, slanted]85 mmHg or receiving treatment for previously diagnosed hypertension; and (4) raised fasting plasma glucose concentration 100 mg/dL (5.6 mM) or known type 2 diabetes mellitus.

Echocardiographic measurements

All studies were performed using SCD-Alpha 7 Aloka Color Doppler Ultrasound Machine with UST-9120 (Manufacturer, address) equipped with tissue Doppler imaging technology. All patients underwent a complete two-dimensional, M mode, color Doppler imaging and TDE. During standard echocardiographic studies, diameters of left atrium, dimensions of left ventricle (LV), thickness of interventricular septum and posterior wall, LV fractional shortening, and ejection fraction were determined using parasternal long-axis approach. Ejection fraction is the fraction of the end-diastolic volume that is ejected with each beat; that is, it is stroke volume (SV) divided by end-diastolic volume (EDV) [16]:


Under the guidance of two-dimensional and M-mode echocardiography, via parasternal long-axis view, left atrial systolic diameter, LV end-systolic diameter, LV end-diastolic diameter, LV posterior wall, and interventricular septum thickness were measured. The LVM was calculated using the formula of Devereux et al. [17], by the following equation: LVM = 0.8 [1.04 × (interventricular septal thickness + posterior wall thickness + end-diastolic diameter)3 − (end-diastolic diameter)3] + 0.6. The LVMI was calculated as LVM divided by the body surface area and measured by g/m2 [by the formula LVMI = LVM/height (m)2.7].

LV diastolic functions were evaluated using Doppler echocardiography and TDE. With apical four-chamber view, the sample volume was placed on mitral valve cusps (LV inflow region), and direction of the Doppler waves were adjusted so as to parallel blood flow. Then peak early (E) and late (A) transmitral filling velocities and E/A ratio were measured. By using TDE, the LV diastolic function was evaluated by the early (Em) diastolic myocardial velocities by recording the mitral Doppler signals in the apical four-chamber view, with the sample volume placed at the lateral walls of mitral annulus.

Statistical analysis

SPSS version 9 (SPSS, Chicago, IL, USA) was used for data analysis. All data were expressed as mean ± standard deviation. The Student t test for quantitative independent variables was used for analysis of difference between two groups. Pearson’s correlation test was used. Analysis of two independent variables was done using a nonparametric test (Mann–Whitney test). In all tests, p < 0.05 was considered significant.


The baseline and laboratory characteristics of 82 obese children and 40 control group are reported in Table 1. BMI, BMI standard deviation score (SDS), heart rate, fasting blood glucose, fasting serum insulin levels, HOMA-IR, total cholesterol, triglycerides, low-density lipoprotein (LDL), serum leptin level, and waist circumference were significantly higher in obese children compared with the control group. Obese children had significantly lower HDL level compared with the control group. The systolic BP and diastolic BP showed no significant difference between both groups. Also, the serum leptin level in obese girls was significantly higher than in obese boys.

Table 1
Clinical and laboratory characteristics of the studied children.

Table 2 shows that the LVMI of obese children was significantly higher compared with the control group (p < 0.001), while ejection fraction and fractional shortening of the left ventricle did not differ significantly in obese versus control group (> 0.05). The diastolic function of the left ventricle in obese children (mitral E wave, A wave, E/A ratio, and Em signal) showed no significant statistical difference when compared with the control group. Doppler echocardiography and TDE measurements did not differ significantly between the two groups (= 0.35).

Table 2
Comparisons of echocardiographic data between obese and control group.

Table 3 shows the clinical and laboratory results, and LVMI in obese children with MS (= 25) and without MS (= 57). MS children had significantly higher LVMI, serum leptin, fasting serum insulin, HOMA, and triglycerides compared to non-MS children, while no significant difference between the MS and non-MS children regarding BMI, BMI-SDS, WC, fasting blood glucose, total cholesterol, LDL, and HDL levels was found (> 0.05).

Table 3
Clinical and laboratory data, and left ventricular mass index (LVMI) in obese children with and without metabolic syndrome (MS).

Table 4 shows that, in both MS and non-MS groups, the serum leptin had a positive correlation with BMI, WC, triglycerides, fasting glucose, fasting insulin, HOMA-IR, and LVMI, but showed a negative correlation with HDL. There was no correlation found between serum leptin in either group with blood pressure, total cholesterol, or LDL.

Table 4
Correlation between serum leptin and various parameters in obese children with and without metabolic syndrome (MS).

Table 5 shows the correlations between LVMI and other measurements in obese children and those of MS. When LVMI was considered as a continuous variable in the whole population of obese children, it was found positively correlated with BMI-SDS, WC, systolic BP, diastolic BP, triglycerides, fasting insulin levels, HOMA-IR and fasting glucose insulin ratio, and negatively correlated with HDL cholesterol.

Table 5
Correlations between left ventricular mass index (LVMI) and cardiovascular risk factors in obese children with and without metabolic syndrome (MS).

In receiver operating characteristic analysis, the results showed that an LVMI value of >38 g/m2 was the best cut-off value in predicting metabolic syndrome in obese children with a sensitivity of 95% and a specificity of 84% (Fig. 3).

Figure 3
Receiver operating characteristic curve of left ventricular mass index cut-off value in predicting metabolic syndrome.


Obesity is an important risk factor for atherosclerotic cardiovascular disease. Risk factor control in young people might retard the progression of atherosclerosis [2]. Therefore, it is very important to study the structural and functional cardiac changes and assess the serum leptin level in obese children and study their relations to parameters of MS in children.

In this study, the obese group showed significant increase in the mean level of triglycerides, total cholesterol, LDL, fasting glucose level, fasting insulin level, and HOMA-IR when compared to the control group. However, the level of HDL showed a significant decrease in obese children when compared to control group. This can be explained and supported by studies that found that both obesity and type 2 diabetes are associated with dyslipidemia and insulin resistance [18], although most obese, insulin-resistant individuals do not develop hyperglycemia unless there is impaired B cell function [19].

In our study, assessment of systolic function by measuring ejection fraction and fractional shortening showed normal results with no significant statistical difference between obese children and control group, and even between MS obese children and non-MS obese children. Similarly, most echocardiographic studies that assessed systolic function in obese individuals showed normal results [20], [21]. Chinali et al. [22] and Pascual et al. [23] reported that a reduction of indices of systolic function was only found in patients with a considerable degree of obesity, suggesting that left ventricular function is affected late in the course of obesity.

The diastolic functions in our obese children (through echo Doppler and TDE) showed no significant statistical difference when compared to control group. Some studies have specifically investigated the impact of obesity on diastolic function in children found normal results by using echo Doppler [24], [25], [26], [27]. In contrast to most results, Harada et al. [28] found altered transmitral and pulmonary venous velocities in 21 obese children using pulse wave Doppler, suggesting a reduction in early diastolic filling. Mehta et al. used TDE to measure the diastolic function in obese children, and revealed impaired diastolic function [29]. Other studies using TDE to assess the effects of childhood obesity on diastolic function have reported similar findings [24], [25], [30], [31].

In this study, the LVMI in obese children was significantly higher when compared to control group and also more significant in MS obese children when compared to non-MS obese children. Moreover, a significantly positive correlation was detected between LVMI and parameters of MS syndrome and also with those of insulin resistance this suggests that MS may have a harmful effect on myocardial structure [32]. Some studies found a relationship between insulin resistance and LVM whereas others found no relationship at all [18], [22], [33], [34], [35], [36]. The association of MS with cardiac hypertrophy might be explained also by nonhemodynamic factors, such as insulin resistance and the accompanying compensatory hyperinsulinemia, which are considered to be the major pathophysiological features underlying the MS [37].

This study demonstrates that leptin levels were significantly higher in obese children when compared with the control group. This finding was confirmed by other studies [38], [39]. Our study confirms previous findings of higher leptin levels in obese girls [40], [41]. This is attributed to inhibitory effect of testosterone on leptin production [42]. Despite good correlation of leptin and BMI, we observed significant variability in leptin levels in individuals with similar BMI. This may be related to differences in body composition and fat distribution. Maffie et al. described significant heterogeneity in leptin concentration in individuals with similar BMI [43]. In our study, a positive correlation was seen between serum leptin with the triglycerides, fasting insulin, fasting glucose, and HOMA-IR and negative correlation was seen with HDL. These observations indicate a role of leptin resistance in the pathogenesis of dyslipidaemia. Leptin levels are shown to predict the development of MS independent of baseline obesity [44]. Some studies found no significant relationship between leptin and lipids [38], [45], whereas another study found that lipids showed significant correlation with leptin levels [46].

Lastly, in this study, the serum leptin was positively correlated with LVMI. This confirms other studies that showed same results in adolescence and young adults [47], [48], although some studies showed no correlation between leptin and LVM [49], or that even higher leptin level was associated with lower LVM [50].


The main findings in the current study are: (1) serum leptin was significantly higher in obese children with MS; (2) obese children with MS had insulin resistance; (3) LVMI was significantly correlated with both serum leptin level and insulin resistance in obese children with MS; and (4) a value of [gt-or-equal, slanted]38 g/m2 LVMI was the optimal cut-off in predicting MS in obese children. We suggest that assessment of LVMI as a routine echocardiographic examination of obese children might be used in predicting the presence of MS and insulin resistance.


Disclosure: Authors have nothing to disclose with regard to commercial support.


Peer review under responsibility of King Saud University.


1. Schonfeld-Warden N., Warden C.H. Pediatric obesity. An overview of etiology and treatment. Pediatr Clin North Am. 1997;44:339–361. [PubMed]
2. McGill H.C., McMahan C.A., Gidding S.S. Preventing heart disease in the 21st century: implications of the pathobiological determinants of atherosclerosis in youth (PDAY) study. Circulation. 2008;117:1216–1227. [PubMed]
3. Cinaz P, Bideci A. Obesity. In: Günöz H, Öcal G, Yordam N, Kurtoğlu S, editors. Pediatrik endokrinoloji. 1. Basım. Pediatrik Endokrinoloji ve Oksoloji Derneği Yayınları 1; 2003. p. 487–5. [In Turkish].
4. Giordano U., Ciampalini P., Turchetta A., Santilli L.A., Calzolari F., Crinò A. Cardiovascular hemodynamics: relationships with insulin resistance in obese children. Pediatr Cardiol. 2003;24:548–552. [PubMed]
5. Kibar A.E., Paç F.A., Oflaz M.B., Ballı S., Ece I. Echocardiographic evaluation of left ventricular function in normotensive obese children: a comparative analysis according to body mass index. Arch Turk Soc Cardiol. 2012;40:337–346. [in Turkish] [PubMed]
6. Cheung B.M., Wat N.M., Tam S., Thomas G.N., Leung G.M., Cheng C.H. Components of the metabolic syndrome predictive of its development: a 6-year longitudinal study in Hong Kong Chinese. Clin Endocrinol. 2008;68:730–737. [PubMed]
7. Kahn B.B., Flier J.S. Obesity and insulin resistance. J Clin Invest. 2000;106:473–481. [PubMed]
8. Ahima RS, Flier JS. Leptin, Annu Rev Physiol 2000;l62:413–437. [PubMed]
9. Friedman J., Halaas J. Leptin and the regulation of body weight in mammals. Nature. 1998;395:763–770. [PubMed]
10. Knudson J.D., Payne G.A., Borbouse L., Tune J.D. Leptin and mechanisms of endothelial dysfunction and cardiovascular disease. Curr Hypertens Rep. 2008;10:434–439. [PubMed]
11. Eyzaguirre F., Mericq V. Insulin resistance markers in children. Horm Res. 2009;71:65–74. [PubMed]
12. Zimmet P., Alberti K.G., Kaufman F., Tajima N., Silink M., Arslanian S. IDF Consensus Group. The metabolic syndrome in children and adolescents—an IDF consensus report. Pediatr Diabetes. 2007;8:299–306. [PubMed]
14. Keilin D., Hartree E.F. The use of glucose oxidase for the determination of glucose in biological material and for the study of glucose-producing systems by manometric methods. Biochem J. 1948;42:230–238. [PubMed]
15. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R. Serum immunoreactive-leptin concentrations in normal weight and obese humans. N Engl Med. 1996;334:292–295. [PubMed]
16. Armstrong W.F., Ryan T., Feigenbaum H. Lippincott Williams & Wilkins; Philadelphia: 2010. Feigenbaum’s echocardiography.
17. Devereux R.B., Alonso D.R., Lutas E.M., Gottlieb G.J., Campo E., Sachs I. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450–458. [PubMed]
18. Zoaira A.M., Muhammada K.T., Desoky E.A., Motawea M.M. Lipid profile and some cardiac functions in children with obesity. Egypt Pediatr Assoc Gazette. 2013;61:15–22.
19. Decsi T., Molnar D. Insulin resistance syndrome in children: pathophysiology and potential management strategies. Pediatr Drugs. 2003;5:291–299. [PubMed]
20. Lauer M.S., Anderson K.M., Levy D. Separate and joint influences of obesity and mild hypertension on left ventricular mass and geometry: the Framingham Heart Study. J Am Coll Cardiol. 1992;19:130–134. [PubMed]
21. Grossman E.F., Oren S.F., Messerli F.M. Left ventricular filling in the systemic hypertension of obesity. Am J Cardiol. 1991;68:57–60. [PubMed]
22. Chinali M., de Simone G., Roman M.J., Lee E.T., Best L.G., Howard B.V. Impact of obesity on cardiac geometry and function in a population of adolescents: the Strong Heart Study. J Am Coll Cardiol. 2006;47:2267–2273. [PubMed]
23. Pascual M., Soria F., Vicente T., Vicente T., Hernández A.M., Tébar F.J. Effects of isolated obesity on systolic and diastolic left ventricular function. Heart. 2003;89:1152–1156. [PubMed]
24. Nienke V.K., Raoul P.R., Lenneke H., Haas L., Verhulst S.L., Desager K.N. Early cardiac abnormalities in obese children: importance of obesity per se versus associated cardiovascular risk factors. Pediatr Res. 2008;64:205–209. [PubMed]
25. Van Putte-Katier N., Rooman R.P., Haas L., Verhulst S.L., Desager K.N., Ramet J. Early cardiac abnormalities in obese children: importance of obesity per se versus associated cardiovascular risk factors. Pediatr Res. 2008;64:205–209. [PubMed]
26. Hirschler V., Acebo H.L., Fernandez G.B., de Luján Calcagno M., Gonzalez C., Jadzinsky M. Influence of obesity and insulin resistance on left atrial size in children. Pediatr Diabetes. 2006;7:39–44. [PubMed]
27. Levent E., Gökşen D., Ozyürek A.R., Darcan S., Coker M. Usefulness of the myocardial performance index (MPI) for assessing ventricular function in obese pediatric patients. Turk J Pediatr. 2005;47:34–38. [PubMed]
28. Harada K., Orino T., Takada G. Body mass index can predict left ventricular diastolic filling in asymptomatic obese children. Pediatr Cardiol. 2001;22:273–278. [PubMed]
29. Mehta S.K., Holliday C., Hayduk L., Wiersma L., Richards N., Younoszai A. Comparisons of myocardial function in children with body mass indexes [gt-or-equal, slanted] 25 versus that <25 kg/m2. Am J Cardiol. 2004;93:1567–1569. [PubMed]
30. Sharpe J.A., Naylor L.H., Jones T.W., Davis E.A., O’Driscoll G., Ramsay J.M. Impact of obesity on diastolic function in subjects [less-than-or-eq, slant]16 years of age. Am J Cardiol. 2006;98:691–693. [PubMed]
31. Yu J.J., Yeom H.H., Chung S., Park Y., Lee D.H. Left atrial diameters in overweight children with normal blood pressure. J Pediatr. 2006;148:321–325. [PubMed]
32. Ilercil A., Devereux R.B., Roman M.J., Paranicas M., O’Grady M.J., Lee E.T. Associations of insulin levels with left ventricular structure and function in American Indians: the strong heart study. Diabetes. 2002;51:1543–1547. [PubMed]
33. Atabek M.E., Pirgon O., Kivrak A.S. Evidence for association between insulin resistance and premature carotid atherosclerosis in childhood obesity. Pediatr Res. 2007;61:345–349. [PubMed]
34. Atabek M.E., Pirgon O., Kurtoglu S. Assessment of abnormal glucose homeostasis and insulin resistance in Turkish obese children and adolescents. Diabetes Obes Metab. 2007;9:304–310. [PubMed]
35. Chinali M., de Simone G., Roman M.J., Best L.G., Lee E.T., Russell M. Cardiac markers of pre-clinical disease in adolescents with the metabolic syndrome: the strong heart study. J Am Coll Cardiol. 2008;52:932–938. [PubMed]
36. Atabek M.E., Akyüz E., Selver Eklioğlu B., Çimen D. The relationship between metabolic syndrome and left ventricular mass index in obese children. J Clin Pediatr Endocrinol. 2011;3:132–138. [PMC free article] [PubMed]
37. Azevedo A., Bettencourt P., Almeida P.B., Santos A.C., Abreu-Lima C., Hense H.W. Increasing number of components of the metabolic syndrome and cardiac structural and functional abnormalities—cross-sectional study of the general population. BMC Cardiovasc Disord. 2007;7:17. [PubMed]
38. Ostlund R.E., Jr, Yang J.W., Klein S., Gingerich R. Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates. J Clin Endocrinol Metab. 1996;81:3909–3913. [PubMed]
39. Sudhisha D., Madhulika K., Anurag B., Pandey R.M., Mahmood H. Serum leptin levels in obese Indian children: relation to clinical and biochemical parameters. Indian Pediatr. 2007;44:257–262. [PubMed]
40. Garcia-Mayor R.V., Andrade M., Rios M., Lage M., Dieguez C., Casanueva F.F. Serum leptin levels in normal children: relationship to age, gender, body mass index, pituitary-gonadal hormones and pubertal stage. J Clin Endocrinol Metab. 1997;82:2849–2855. [PubMed]
41. Nagy T.R., Gower B.A., Trowbridge C.A., Dezenberg C., Shewchuk R.M., Goran M.I. Effects of gender, ethnicity, body composition and fat distribution on serum leptin concentration in children. J Clin Endocrinol Metab. 1997;82:2148–2152. [PubMed]
42. Wabitsch M., Blum W.F., Muche R., Braun M., Hube F., Rashcer W. Contribution of androgens to the gender difference in leptin production in obese children and adolescents. J Clin Invest. 1997;100:808–813. [PubMed]
43. Maffei M., Halaas J., Ravussin E., Pratley R.E., Lee G.H. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med. 1995;1:1155–1161. [PubMed]
44. Franks P.W., Brage S., Luan J., Ekelund U., Rahman M., Farooqi I.S. Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. Obes Res. 2005;13:1476–1484. [PubMed]
45. Misra A., Arora N., Mondal S., Pandey R.M., Jailkhani B., Peshin S. Relation between plasma leptin and anthropometric and metabolic covariates in lean and obese diabetic and hyperlipidaemic Asian Northern Indian subjects. Diabetes Nutr Metab. 2001;14:18–26. [PubMed]
46. Tamer L., Ercan B., Unlu A., Sucu N., Pekdemir H., Eskandari G. The relationship between leptin and lipids in atherosclerosis. Indian Heart J. 2002;54:692–696. [PubMed]
47. Paolisso G., Tagliamonte M.R., Galderisi M., Zito G.A., Petrocelli A., Carella C. Plasma insulin level associated with myocardial wall thickness in hypertensive insulin- resistant men. Hypertension. 1999;34:1047–1052. [PubMed]
48. Soderberg S., Ahern B., Janson J.H., Johonson O., Hallmans G., Asplund K. Leptin is associated with increased risk of myocardial infarction. J Intern Med. 1999;246 409–409. [PubMed]
49. Ormond D.K. Leptin resistance and left ventricular hypertrophy in obese children and adolescents. Student Scholar Arch. 2012:722.
50. Pladevall M., Williams K., Guyer H., Sadurni J., Falces C., Ribes A. The associations between leptin and left ventricular hypertrophy: a population-based cross-sectional study. J Hypertens. 2003;21:1467–1473. [PubMed]

Articles from Journal of the Saudi Heart Association are provided here courtesy of Elsevier